Does Tamoxifen Cause Fatigue and Other Side Effects?

Tamoxifen does cause fatigue in some people, though tiredness is one of the trickier side effects to pin down because large clinical trials have not consistently measured it as a standalone outcome. What the research shows more clearly is a wide constellation of other side effects, from hot flashes and joint pain to rarer but serious risks like blood clots and uterine changes. The side-effect profile is broad enough, and variable enough from person to person, that understanding the full picture matters if you are starting tamoxifen, already taking it, or weighing whether to continue.

The Fatigue Question Specifically

Fatigue is one of the most common complaints among people taking tamoxifen, yet it is surprisingly underrepresented in the formal trial literature. In a large side study of the TEAM trial comparing tamoxifen to the aromatase inhibitor exemestane, the main quality-of-life finding was that exemestane caused more insomnia; overall quality of life and most functioning scores actually improved over the course of treatment in both groups.¹ That does not mean fatigue is imaginary. It means the structured questionnaires used in many trials tend to capture fatigue indirectly, through measures of physical functioning, sleep quality, or general well-being, rather than as a discrete symptom.

Patient surveys tell a different story. When researchers directly asked tamoxifen users and aromatase inhibitor users what bothered them most, insomnia was reported by roughly one in six in both groups, and many described persistent low energy alongside other symptoms like hot flashes and weight gain.² The practical takeaway is that fatigue on tamoxifen is real and common, but it often intertwines with disrupted sleep, vasomotor symptoms, and mood changes rather than existing in isolation.

Hot Flashes and Night Sweats

If tamoxifen has a signature side effect, it is hot flashes. Among women taking tamoxifen in a large breast cancer study, roughly four out of five reported them.³ The flashes happen because tamoxifen blocks estrogen receptors in the hypothalamus, the part of the brain that regulates body temperature. Without estrogen’s usual input, the thermostat essentially becomes oversensitive, triggering sudden waves of heat and sweating.

Night sweats are the nocturnal version of the same phenomenon and a major driver of the sleep problems that feed into daytime fatigue. In one study, disturbed sleep was the second most common complaint on tamoxifen, reported by over half of patients.⁴ For many people, managing hot flashes and sleep disruption is the single most impactful thing they can do to improve how they feel overall while on the drug.

Uterine and Endometrial Changes

Tamoxifen blocks estrogen in breast tissue but acts more like estrogen in the uterus. This is one of its most important safety trade-offs. A large Korean cohort study of premenopausal women found that tamoxifen use was independently associated with roughly a fourfold increase in the risk of endometrial polyps and a nearly sixfold increase in the risk of endometrial hyperplasia, along with a nearly fourfold higher risk of endometrial cancer.⁵ A separate meta-analysis pooling data from over two hundred thousand patients confirmed that tamoxifen roughly doubled the overall risk of endometrial cancer, with the risk climbing as dose and duration increased.⁶

When tamoxifen is extended beyond the standard five years, the endometrial risk grows further. A meta-analysis found the cumulative risk of endometrial malignancy roughly doubled from about 1.5 percent to about 3.2 percent when therapy continued past the five-year mark.⁷ The landmark ATLAS trial, which studied ten years of tamoxifen versus five, found a similar pattern: the cumulative endometrial cancer risk over years five through fourteen was about 3.1 percent in the extended group versus 1.6 percent in controls.⁸ Any unusual vaginal bleeding on tamoxifen warrants prompt evaluation.

Blood Clots and Cardiovascular Effects

Tamoxifen increases the risk of venous blood clots, including deep vein thrombosis and pulmonary embolism. A Danish population-based study found that the five-year risk of DVT or pulmonary embolism was about 1.2 percent for women on tamoxifen compared to 0.5 percent for women not on it. The risk was highest in the first two years of treatment, with roughly a threefold increase during that window, and then tapered.⁹ An earlier case-control study estimated the relative risk even higher, at about sevenfold during active tamoxifen use compared to never or past use, though that was a smaller study with wide confidence intervals.¹⁰

Aromatase inhibitors carry a lower clot risk by comparison. One study of breast cancer survivors found that switching to an aromatase inhibitor was associated with at least a 40 percent lower risk of venous thromboembolism than continuing tamoxifen.¹¹ On the other hand, the ATLAS trial found that extended tamoxifen was associated with a modest reduction in ischemic heart disease, so the cardiovascular picture is not uniformly negative.⁸ If you have a personal or family history of blood clots, your oncologist will likely weigh this carefully when choosing your endocrine therapy.

Effects on Bone Density

Tamoxifen’s effect on bone depends entirely on whether you are premenopausal or postmenopausal, and getting this nuance right matters. In premenopausal women, tamoxifen causes bone loss. A study measuring bone density over three years found that premenopausal women on tamoxifen lost an average of about 1.4 percent of lumbar spine density per year, while those on placebo gained slightly. In postmenopausal women, the opposite happened: tamoxifen preserved bone, with spine density increasing by about 1.2 percent per year and hip density by about 1.7 percent per year, while those on placebo lost bone.¹²

The explanation is that in premenopausal women, natural estrogen levels are high, and tamoxifen competes with that estrogen at the bone receptor, acting as a partial blocker. In postmenopausal women, estrogen levels are already very low, so even tamoxifen’s weak estrogen-like activity at bone receptors is better than nothing. If you are premenopausal and taking tamoxifen for several years, your doctor may monitor bone density and discuss calcium, vitamin D, or weight-bearing exercise.

Cognitive Effects

Many people on tamoxifen report feeling mentally foggy, and the research increasingly supports this as a real pharmacological effect rather than a stress response. A study comparing tamoxifen patients to matched controls found that patients performed worse on tests of verbal learning, processing speed, executive functioning, and motor functioning. Cognitive complaints were described as mild, but they were consistently present, and higher blood levels of tamoxifen and its active metabolite endoxifen were associated with worse performance across several domains.¹³

Animal research has suggested one possible mechanism. In rats given tamoxifen orally over a long period, levels of a brain growth factor called BDNF dropped in the hippocampus, a region critical for memory and learning.¹⁴ Translating animal findings to humans always requires caution, but the pairing of patient complaints, measurable cognitive test differences, and a plausible biological mechanism makes this one of the more solidly supported “softer” side effects.

Mood and Depression

Mood changes are frequently mentioned among tamoxifen complaints, but the evidence for clinical depression caused by tamoxifen is weaker than many people assume. One study that specifically tracked new-onset depression in breast cancer patients found that the risk in the tamoxifen group was not significantly different from those not taking tamoxifen.¹⁵ That does not mean you cannot feel emotionally off on tamoxifen. Hot flashes, disrupted sleep, cognitive fog, sexual changes, and the general experience of taking a daily cancer drug can all contribute to low mood without crossing the threshold of major depressive disorder. The distinction matters because it affects how you and your doctor choose to address it.

Sexual Health and Vaginal Symptoms

Tamoxifen’s impact on sexual well-being is substantial and underreported. In one study, over half of patients reported pain, burning, or discomfort during intercourse. Vaginal dryness was the most common underlying complaint, and it was paradoxically associated with the presence of estrogen-like effects on vaginal tissue, suggesting tamoxifen’s partial estrogen activity in the reproductive tract creates a confusing mixed signal.¹⁶

A separate study found that decreased sexual desire was reported by about 44 percent of patients, a figure that did not differ between premenopausal and postmenopausal women. Vaginal dryness and painful intercourse were strongly linked to decreased desire, and about 30 percent of sexually active patients reduced or stopped sexual activity because of these symptoms.¹⁷ These are quality-of-life issues that patients often hesitate to bring up with their oncologist but that can be meaningfully helped with vaginal moisturizers and other interventions.

Liver and Metabolic Changes

Tamoxifen can cause fatty liver disease, and it does so at surprisingly high rates. A systematic review and meta-analysis found that the prevalence of fatty liver among breast cancer patients taking tamoxifen was about 40 percent, and the incidence was roughly three times higher in tamoxifen users than in control groups.¹⁸ Higher body mass index and cholesterol levels increased the risk further.¹⁹

The reassuring part is that the fatty liver induced by tamoxifen appears to be largely reversible. In one study that tracked liver changes over time, about 43 percent of patients developed some degree of fatty liver within the first two years, ranging from mild to severe. But after tamoxifen was stopped, most recovered to normal liver density within an average of about 1.2 years, and none progressed to serious liver disease like cirrhosis.²⁰ Still, if you are already at risk for metabolic syndrome or fatty liver, your doctor may want to monitor liver function during treatment.

Eye Problems

Tamoxifen can affect the eyes, though serious damage is uncommon at standard doses. Case reports and reviews have identified crystalline deposits on the retina, macular edema, and corneal changes as potential toxicities, with extensive retinal damage and vision loss mostly reported in patients on high doses that are no longer standard practice.²¹ At the lower doses used today, the main concern is a modestly increased risk of cataracts with long-term use. One study found that women who took tamoxifen for five or more years had a roughly 70 percent higher relative risk of cataracts compared to non-users.²² Another study found that posterior subcapsular opacities, a type of cataract that particularly affects near vision, were about four times more common in the tamoxifen group.²³ Routine eye exams during long-term tamoxifen therapy are a reasonable precaution.

Why Side Effects Vary So Much Between People

Tamoxifen itself is actually a prodrug. Your liver converts it into its active form, endoxifen, using an enzyme called CYP2D6. People carry different genetic versions of the gene for this enzyme, and the version you have can dramatically change how much active drug your body produces. Early research found that women who were genetically poor metabolizers of CYP2D6 had fewer hot flashes, which makes sense: less endoxifen means less anti-estrogen effect, and therefore fewer of the side effects driven by estrogen blockade.²⁴

A recent study found that this pattern is especially pronounced for uterine changes: rapid metabolizers had far fewer uterine side effects than slow metabolizers, while other symptoms like joint pain, hot flashes, and fatigue did not show a clear link to metabolizer status.²⁵ The broader picture, though, remains complicated. After more than a decade of research, there is still no consensus on whether CYP2D6 genotyping should guide routine treatment decisions, because studies on how genotype affects cancer outcomes have given conflicting results.²⁶

Drug Interactions That Can Be Dangerous

Because tamoxifen depends on CYP2D6 to become active, drugs that block this enzyme can blunt tamoxifen’s effectiveness. The most concerning culprits are certain antidepressants, particularly paroxetine and fluoxetine, which are strong CYP2D6 inhibitors. A large population-based study found that overlapping use of paroxetine during tamoxifen treatment was associated with a dose-dependent increase in the risk of dying from breast cancer: women who took paroxetine during a quarter of their tamoxifen treatment had a 24 percent higher risk of breast cancer death, while those who overlapped for three-quarters of their treatment had a 91 percent higher risk. Other antidepressants did not show this pattern.²⁷

This is a particularly tricky problem because antidepressants and hot-flash medications are among the drugs most commonly prescribed alongside tamoxifen. Clinical guidelines now recommend avoiding potent CYP2D6-inhibiting antidepressants in tamoxifen users.²⁸ Alternatives like venlafaxine, which is a weaker CYP2D6 inhibitor, are considered safer options for managing depression or hot flashes during tamoxifen therapy.

Sticking With Treatment When Side Effects Mount

Roughly a third of patients who start tamoxifen do not finish the recommended five-year course. Those who experienced severe side effects early on, or who developed new side effects over time, were more likely to stop.²⁹ Qualitative research has shown that the decision to continue or quit often comes down to whether a patient feels the cancer-prevention benefits outweigh the daily burden of side effects. A middle group, who believed in the importance of treatment but struggled with symptoms, were often non-adherent in practice even while intending to comply.³⁰

One obstacle is that the gap between how side effects are captured in clinical trials and how patients actually experience them is enormous. A trial comparing low-dose tamoxifen with placebo found that when researchers relied on standard physician-reported grading, only a handful of hot flash events were recorded at each time point. But when the same patients reported their own experiences through questionnaires, hundreds of hot flash events were captured. At 12 months, for example, patients reported about 246 hot flash events while physician grading captured only 12.³¹ This discrepancy helps explain why clinical trial reports can understate the symptom burden that patients deal with daily.

Tamoxifen Side Effects in Men

Tamoxifen is also used in male breast cancer and sometimes in other conditions, and the side-effect profile in men is not a mirror image of the one in women. A retrospective review of 64 male breast cancer patients found that over half experienced at least one side effect on tamoxifen. The most common were weight gain and sexual dysfunction, each reported by about 22 percent of patients. About 20 percent of men discontinued tamoxifen due to toxicity, with blood clots being the most common reason for stopping.³²

A broader review of adverse events across male tamoxifen users found that gastrointestinal and cardiovascular problems were the most frequently reported in prostate cancer patients taking the drug, while psychiatric side effects were more common among male breast cancer patients.³³ Sexual side effects in men also appear to go beyond libido: a pilot study found measurable declines in erectile function, orgasmic function, and sexual desire during tamoxifen treatment.³⁴

Exercise as a Tool for Managing Symptoms

Among the non-drug approaches to tamoxifen side effects, aerobic exercise has the most consistent evidence behind it. A systematic review of exercise interventions for breast cancer survivors on hormone therapy found that aerobic programs provided clear improvements in both fatigue and sleep disturbances.³⁵ This aligns with the broader cancer survivorship literature, where exercise has been shown to help with everything from energy levels to mood. It does not eliminate symptoms, but for a drug you may take for five to ten years, even modest daily improvements in energy and sleep can make a meaningful difference in whether you stay on treatment long enough for it to do its job.